<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00837083</url>
  </required_header>
  <id_info>
    <org_study_id>NIS-CSI-CRE-2006/1</org_study_id>
    <secondary_id>NIS-CRE 01/06</secondary_id>
    <nct_id>NCT00837083</nct_id>
  </id_info>
  <brief_title>Evaluation of Crestor® (Rosuvastatin) in Daily Practice</brief_title>
  <official_title>Open-Label Non-Interventional Evaluation of Efficacy of Crestor® (Rosuvastatin) in Reduction of LDL-Cholesterol and Cardiovascular Risk Parameters in Patients With Hypercholesterolaemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This open label, non-interventional study is to show the efficacy of Crestor (rosuvastatin)
      in reduction of LDL-cholesterol and cardiovascular risk parameters in patients with
      hypercholesterolemia. Effectiveness is to be evaluated using the difference in LDL
      cholesterol level between the first and the second visit after 12 weeks.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2007</start_date>
  <completion_date type="Actual">October 2007</completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>LDL-cholesterol reduction</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>achievement of target levels of total cholesterol and LDL-cholesterol</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>patient compliance</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in coronary risk</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">602</enrollment>
  <condition>Hypercholesterolemia</condition>
  <eligibility>
    <study_pop>
      <textblock>
        patients (outpatient or hospitalised) in whom Crestor is indicated according to the current
        Summary of product characteristics (SPC)
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  a patient with hypercholesterolemia who has been prescribed Crestoraccording to
             physician's judgement, irrespective of the inclusion in the study.

          -  no treatment with any statin in the last 3 months

        Exclusion Criteria:

          -  hypersensitivity to rosuvastatin or any other ingredient of Crestor

          -  active liver disease, severe renal insufficiency

          -  myopathy or predisposing risk factors for myopathy/ rhabdomyolysis

          -  woman of child-bearing potential and not using appropriate contraceptive measures,
             pregnancy or lactation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Matija Cevc, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Medical Centre Ljubljana</affiliation>
  </overall_official>
  <verification_date>February 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 4, 2009</study_first_submitted>
  <study_first_submitted_qc>February 4, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 5, 2009</study_first_posted>
  <last_update_submitted>February 5, 2009</last_update_submitted>
  <last_update_submitted_qc>February 5, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 6, 2009</last_update_posted>
  <responsible_party>
    <name_title>Meta Jeras; Regulatory and Medical Affairs Manager</name_title>
    <organization>AstraZeneca</organization>
  </responsible_party>
  <keyword>hypercholesterolemia</keyword>
  <keyword>cholesterol</keyword>
  <keyword>LDL-cholesterol</keyword>
  <keyword>rosuvastatin</keyword>
  <keyword>Crestor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypercholesterolemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rosuvastatin Calcium</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

